Quick Answer
Amphastar Pharmaceuticals, Inc. reported Total Revenue of $719.89 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $719.89M | -1.7% |
| 2024 | $731.97M | +13.6% |
| 2023 | $644.39M | +29.1% |
| 2022 | $498.99M | +14.0% |
| 2021 | $437.77M | +25.1% |
| 2020 | $349.85M | +8.5% |
| 2019 | $322.36M | +9.4% |
| 2018 | $294.67M | +22.7% |
| 2017 | $240.18M | -5.9% |
| 2016 | $255.16M | +1.4% |
| 2015 | $251.52M | +19.5% |
| 2014 | $210.46M | -8.4% |
| 2013 | $229.68M | +12.4% |
| 2012 | $204.32M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $191.84M | +0.3% | +10.0% |
| June 30, 2025 | $174.41M | -4.4% | +2.3% |
| March 31, 2025 | $170.53M | -0.8% | -10.8% |
| September 30, 2024 | $191.21M | +5.9% | +4.8% |
| June 30, 2024 | $182.39M | +25.2% | +6.1% |
| March 31, 2024 | $171.84M | +22.7% | -4.8% |
| September 30, 2023 | $180.56M | +50.3% | +23.9% |
| June 30, 2023 | $145.71M | +18.0% | +4.1% |
- Amphastar Pharmaceuticals, Inc. showed a decrease of -1.7% in Total Revenue compared to the prior fiscal year.
- Over the 2012–2025 period, Amphastar Pharmaceuticals, Inc.’s total revenue has grown by 252.3% (from $204.32 million to $719.89 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: